Filter by: patients
Home > Community Treatment Reports and Side Effects > Tri-mix Injection Treatment Report
What is Tri-mix Injection?

Tri-mix is a compounded product that includes papaverine, regitine and prostaglandine E-1. It is an injectable three-drug cocktail used to treat erectile dysfunction.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Erectile dysfunction 1 1 Efficacy_slight
Sexual dysfunction 1 1 Efficacy_major
Erectile Dysfunction 1 1 Efficacy_cant_tell

See all 2 patients currently taking Tri-mix Injection

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 2

Commonly reported side effects, conditions, and hospitalizations associated with Tri-mix Injection

Pain 1

Reported Dosages

  20mg as needed 2.5other as needed
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Tri-mix Injection (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 50%
Other 1   Other: 50%

See all 2 patients who’ve stopped taking Tri-mix Injection

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Tri-mix Injection

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Tri-mix Injection

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Tri-mix Injection

Always
 1 33%
Usually
 0 0%
Sometimes
 1 33%
Never
 1 33%

Burden

Difficulty being on treatment

Burden of Tri-mix Injection

Very
 2 67%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 33%

Cost

Paid out of pocket

Cost of Tri-mix Injection

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

Report created on May 27, 2012.